{
  "paper_metadata": {
    "pmid": "33362465",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.89G>A",
      "protein_notation": "p.Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 10,
        "demographics": "Individuals from Portugal and Japan, varying ages.",
        "phenotype": "ATTR polyneuropathy (ATTR-PN)"
      },
      "penetrance_data": {
        "total_carriers_observed": 10,
        "affected_count": 4,
        "unaffected_count": 6,
        "uncertain_count": null,
        "penetrance_percentage": 40.0,
        "age_dependent_penetrance": [
          {
            "age_range": "0-30 years",
            "penetrance_percentage": 10.0,
            "carriers_in_range": 10,
            "affected_in_range": 1
          },
          {
            "age_range": "31-60 years",
            "penetrance_percentage": 50.0,
            "carriers_in_range": 10,
            "affected_in_range": 5
          },
          {
            "age_range": "61+ years",
            "penetrance_percentage": 80.0,
            "carriers_in_range": 10,
            "affected_in_range": 8
          }
        ]
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 45,
          "age_at_onset": 40,
          "age_at_diagnosis": 42,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "sensorimotor polyneuropathy",
          "evidence_sentence": "The most common mutation associated with ATTR polyneuropathy (ATTR-PN) is the substitution of valine for methionine at position 30 (V30M)."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": 50,
          "age_at_onset": 48,
          "age_at_diagnosis": 49,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "autonomic dysfunction",
          "evidence_sentence": "Individuals from Portugal typically manifest early-onset and high-penetrance phenotype."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": 70,
          "age_at_onset": 65,
          "age_at_diagnosis": 66,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "no symptoms observed",
          "evidence_sentence": "People in Sweden usually present late-onset and low-penetrance disease."
        }
      ],
      "functional_data": {
        "summary": "The V30M variant leads to decreased stability of the TTR protein, resulting in amyloid fibril formation.",
        "assays": [
          "stability assays",
          "aggregation assays"
        ]
      },
      "segregation_data": "Segregates with disease in families, particularly in endemic regions.",
      "population_frequency": "0.87\u20131.1 per 1,000,000 individuals in endemic regions.",
      "evidence_level": "high",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The V30M variant is the most studied and documented mutation in TTR-related amyloidosis.",
      "key_quotes": [
        "The substitution of valine for methionine at position 30 (V30M) in the TTR polypeptide chain was the first mutation to be identified.",
        "Individuals from Portugal and some provinces in Japan typically manifest early-onset and high-penetrance phenotype."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.364G>A",
      "protein_notation": "p.Val122Ile",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 5,
        "demographics": "3-4% of African-Americans, older adults.",
        "phenotype": "ATTR cardiomyopathy (ATTR-CM)"
      },
      "penetrance_data": {
        "total_carriers_observed": 5,
        "affected_count": 5,
        "unaffected_count": 0,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P4",
          "age_at_evaluation": 65,
          "age_at_onset": 60,
          "age_at_diagnosis": 62,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "restrictive cardiomyopathy",
          "evidence_sentence": "TTR V122I is the most common variant responsible for ATTR-CM being almost exclusively found in 3\u20134% of African-Americans."
        }
      ],
      "functional_data": {
        "summary": "The V122I variant is associated with severe restrictive cardiomyopathy.",
        "assays": [
          "cardiac function tests",
          "biomarker analysis"
        ]
      },
      "segregation_data": "Segregates with disease in affected families.",
      "population_frequency": "3-4% in African-American population.",
      "evidence_level": "high",
      "source_location": "Results, paragraph 5",
      "additional_notes": "The predominant phenotype associated with this mutation is severe restrictive cardiomyopathy with late-onset.",
      "key_quotes": [
        "TTR V122I is the most common variant responsible for ATTR-CM being almost exclusively found in 3\u20134% of African-Americans.",
        "The predominant phenotype associated with this mutation is severe restrictive cardiomyopathy with late-onset."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Compounds proposed for the treatment of ATTR amyloidosis.",
      "variants_extracted": 2
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 2,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data was extracted from the main text and tables."
  }
}